Funded by the European Union
AstraZeneca is a global, innovation and research-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, renal, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries. The innovative portfolio of medicines of AstraZeneca are used by millions of patients worldwide. AstraZeneca is working across biologics, small molecules, immuno- and nucleotide therapies, protein engineering and devices.
AstraZeneca Structure and Biophysics has state-of-the-art crystallisation facilities and access to fragment screening libraries (subject to approval for publication). AstraZeneca Pharmaceutical Technology & Development have state-of-the-art facilities for late phase pharmaceutical development. Taking a target substance from early-clinical to a finished drug product. The material science / solid-state laboratories are well equipped. The instrumentation include: x-ray powder diffraction (2 PANalytical, 1 Bruker instruments), µCT (Bruker SkyScan 1272 11Mp with 3-5 µm resolution), TOFS-SIMS, Raman Microscopy (Renishaw InVia Qontor), R5 FT-Raman (Bruker), DSC (multiple instruments), TGA (multiple instruments), GVS (multiple instruments ), TAM (µ-caliometry), SEM (GeminiSEM 300 by ZEISS with a resolution down to 0.7 nm), Crystal Breeder, NIR (Bruker MPA Multi-Purpose FT-NIR Analyzer), and much more.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska Curie grant agreement No 956099.